Suberoylanilide Hydroxamic Acid CAS 149647-78-9

Product Description:

Product Name: Suberoylanilide Hydroxamic Acid CAS NO: 149647-78-9  

Synonyms:

N-Hydroxy-N'-phenyloctanediamide;

Vorinostat/SAHA;

Chemical & Physical Properties:

Appearance: White crystalline solid

Assay :≥99.00%

Density: 1.174 g/cm3

Melting Point: 161-162℃

Refractive Index: 1.566

Safety Information:

RTECS: SJ7453000

Safety Statements: S53; S45; S24/25; S22; S36

HS Code: 29349990

WGK Germany: 3

RIDADR: UN 2265 3/PG 3

Risk Statements: R61; R20/21; R36; R36/37/38; R20/21/22

Hazard Codes: T; Xn

Signal Word: Danger

Hazard Declaration: H341; H360

Symbol: GHS08

Caution Statements: P201; P281; P308 + P313

Vorinostat (rINN) also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.

Vorinostat is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.